(Q44131214)

English

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial

scientific article published on 14 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Florence Joly

1

0 references

9

object named as

Ignace Vergote

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Isabelle Ray-Coquard

2

object named as

Isabelle Ray-Coquard

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Michel Fabbro

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Mark Donoghoe

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Karin Boman

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Akira Sugimoto

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Michelle Vaughan

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Alexander Reinthaller

8

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Gabriella Ferrandina

10

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Tiziana Dell'Anna

11

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Jens Huober

12

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Eric Pujade-Lauraine

13

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

language of work or name

0 references

publication date

14 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

122

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

226-232

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Anaphylaxis to carboplatin following multiple previous uncomplicated courses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Clinical features of hypersensitivity reactions to carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Carboplatin hypersensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Carboplatin hypersensitivity in children. A report of five patients with brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitization

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Death from anaphylaxis to cisplatin: a case report

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

A modified, prolonged desensitization protocol in carboplatin allergy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (A

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Carboplatin hypersensitivity: case reports and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

IgE antibody-specific activity in human allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

T-cell receptor repertoire expression in workers with occupational asthma due to platinum salt

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Delayed Drug Hypersensitivity Reactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Pegylation: a novel process for modifying pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Pharmacokinetic consequences of pegylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

[Hypersensitivity to carboplatin. An effect of generic drugs?]

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Prevention and management of antineoplastic-induced hypersensitivity reactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.019

7 January 2021

Identifiers

10.1016/J.YGYNO.2011.04.019

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44131214&oldid=2150710360"